نتایج جستجو برای: pd l2

تعداد نتایج: 79105  

2016
Yusuke Inoue Katsuhiro Yoshimura Kazutaka Mori Nobuya Kurabe Tomoaki Kahyo Hiroki Mori Akikazu Kawase Masayuki Tanahashi Hiroshi Ogawa Naoki Inui Kazuhito Funai Kazuya Shinmura Hiroshi Niwa Takafumi Suda Haruhiko Sugimura

New reliable biomarkers are needed to predict the response to immune checkpoint inhibitors against programmed death-1 (PD-1) and its ligand (PD-L1), because PD-L1 expression on tumor cells has limited power for selecting patients who may benefit from such therapy. Here we investigated the significance of PD-L1 and PD-L2 gene copy number gains using fluorescence in situ hybridization as well as ...

Journal: :Nature Immunology 2014

2010
Silke Huber Reinhard Hoffmann Femke Muskens David Voehringer

Alternatively activated macrophages (AAM) accumulate in tissues during Th2associated immune responses like helminth infections and allergic disorders. These cells differentiate in response to interleukin 4 (IL-4)/IL-13–mediated activation of Stat6 and possess potent inhibitory activity against T cells. The molecular mechanism that leads to T-cell suppression remains unclear and could involve so...

Journal: :Blood 2010
Silke Huber Reinhard Hoffmann Femke Muskens David Voehringer

Alternatively activated macrophages (AAM) accumulate in tissues during Th2-associated immune responses like helminth infections and allergic disorders. These cells differentiate in response to interleukin 4 (IL-4)/IL-13-mediated activation of Stat6 and possess potent inhibitory activity against T cells. The molecular mechanism that leads to T-cell suppression remains unclear and could involve s...

2012
Esdy N. Rozali Stanleyson V. Hato Bruce W. Robinson Richard A. Lake W. Joost Lesterhuis

Inhibitory molecules of the B7/CD28 family play a key role in the induction of immune tolerance in the tumor microenvironment. The programmed death-1 receptor (PD-1), with its ligands PD-L1 and PD-L2, constitutes an important member of these inhibitory pathways. The relevance of the PD-1/PD-L1 pathway in cancer has been extensively studied and therapeutic approaches targeting PD-1 and PD-L1 hav...

Journal: :Blood 2013
Asim Saha Kazutoshi Aoyama Patricia A Taylor Brent H Koehn Rachelle G Veenstra Angela Panoskaltsis-Mortari David H Munn William J Murphy Miyuki Azuma Hideo Yagita Brian T Fife Mohammed H Sayegh Nader Najafian Gerard Socie Rafi Ahmed Gordon J Freeman Arlene H Sharpe Bruce R Blazar

Programmed death 1 (PD-1) and its ligands, PD-L1 and PD-L2, play an important role in the maintenance of peripheral tolerance. We explored the role of PD-1 ligands in regulating graft-versus-host disease (GVHD). Both PD-L1 and PD-L2 expression were upregulated in the spleen, liver, colon, and ileum of GVHD mice. Whereas PD-L2 expression was limited to hematopoietic cells, hematopoietic and endo...

Journal: :Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016
Margaretha G M Roemer Ranjana H Advani Azra H Ligon Yasodha Natkunam Robert A Redd Heather Homer Courtney F Connelly Heather H Sun Sarah E Daadi Gordon J Freeman Philippe Armand Bjoern Chapuy Daphne de Jong Richard T Hoppe Donna S Neuberg Scott J Rodig Margaret A Shipp

PURPOSE Classical Hodgkin lymphomas (cHLs) include small numbers of malignant Reed-Sternberg cells within an extensive but ineffective inflammatory/immune cell infiltrate. In cHL, chromosome 9p24.1/PD-L1/PD-L2 alterations increase the abundance of the PD-1 ligands, PD-L1 and PD-L2, and their further induction through Janus kinase 2-signal transducers and activators of transcription signaling. T...

2017
Carlos A. Morales-Betanzos Hyoungjoo Lee Paula I. Gonzalez Ericsson Justin M. Balko Douglas B. Johnson Lisa J. Zimmerman Daniel C. Liebler

Quantitative assessment of key proteins that control the tumor-immune interface is one of the most formidable analytical challenges in immunotherapeutics. We developed a targeted MS platform to quantify programmed cell death-1 (PD-1), programmed cell death 1 ligand 1 (PD-L1), and programmed cell death 1 ligand 2 (PD-L2) at fmol/microgram protein levels in formalin fixed, paraffin-embedded secti...

2017
Hyunsoo Cho Se Hoon Kim Soo-Jeong Kim Jong Hee Chang Woo-Ick Yang Chang-Ok Suh Yu Ri Kim Ji Eun Jang June-Won Cheong Yoo Hong Min Jin Seok Kim

Programmed cell death 1 (PD-1) and its ligands PD-L1/PD-L2 have been shown to mediate immune evasion in various cancers, but their prognostic implications in patients with primary central nervous system lymphoma (PCNSL) are poorly understood. Therefore, we analyzed 76 PCNSL patients at initial diagnosis who were treated homogenously with high-dose methotrexate-based chemotherapy, and evaluated ...

2015
Sarah Derks Katie S. Nason Xiaoyun Liao Matthew D. Stachler Kevin X. Liu Jie Bin Liu Ewa Sicinska Michael S. Goldberg Gordon J. Freeman Scott J. Rodig Jon M. Davison Adam J. Bass

Esophageal adenocarcinoma is an increasingly common disease with a dismal 5-year survival rate of 10% to 15%. In the first systematic evaluation of the PD-1 pathway in esophageal adenocarcinoma, we identify expression of PD-L2 in cancer cells in 51.7% of esophageal adenocarcinomas. Epithelial PD-L1 was expressed on only 2% of cases, although PD-L1þ immune cells were observed in 18% of esophagea...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید